| Drug General Information |
| Drug ID |
D03QOD
|
| Former ID |
DNC009953
|
| Drug Name |
N-hydroxy-2,2-diphenylacetamide
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Investigative |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C14H13NO2
|
| Canonical SMILES |
C1=CC=C(C=C1)C(C2=CC=CC=C2)C(=O)NO
|
| InChI |
1S/C14H13NO2/c16-14(15-17)13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10,13,17H,(H,15,16)
|
| InChIKey |
OFSBBVCLWMCGNY-UHFFFAOYSA-N
|
| PubChem Compound ID |
|
| Target and Pathway |
| Target(s) |
Histone deacetylase 4 |
Target Info |
Inhibitor |
[1]
|
|---|
| Histone deacetylase |
Target Info |
Inhibitor |
[1]
|
|
KEGG Pathway
|
Alcoholism
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
MicroRNAs in cancer
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
Pathway Interaction Database
|
Signaling events mediated by HDAC Class II
|
|
Signaling events mediated by HDAC Class III
|
|
Signaling events mediated by HDAC Class I
|
|
Sumoylation by RanBP2 regulates transcriptional repression
|
|
Validated nuclear estrogen receptor alpha network
|
|
Reactome
|
NOTCH1 Intracellular Domain Regulates Transcription
|
|
Constitutive Signaling by NOTCH1 PEST Domain Mutants
|
|
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
|
|
WikiPathways
|
Endochondral Ossification
|
|
Cardiac Hypertrophic Response
|
|
Neural Crest Differentiation
|
|
miR-targeted genes in muscle cell - TarBase
|
|
miR-targeted genes in lymphocytes - TarBase
|
|
miR-targeted genes in epithelium - TarBase
|
|
TarBasePathway
|
|
Cell Cycle
|
|
MicroRNAs in cardiomyocyte hypertrophy
|
| References |
| REF 1 | Bioorg Med Chem Lett. 2009 Oct 1;19(19):5684-8. Epub 2009 Aug 7.Diphenylmethylene hydroxamic acids as selective class IIa histone deacetylase inhibitors. |
|---|
